GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (NAS:ADVM) » Definitions » Owner Earnings per Share (TTM)

Adverum Biotechnologies (Adverum Biotechnologies) Owner Earnings per Share (TTM) : -7.97 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Adverum Biotechnologies Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Adverum Biotechnologies's Owner Earnings per Share (TTM) ended in Mar. 2024 was $-7.97. It's Price-to-Owner-Earnings ratio for today is 0.


The historical rank and industry rank for Adverum Biotechnologies's Owner Earnings per Share (TTM) or its related term are showing as below:



ADVM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.67
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Adverum Biotechnologies's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.50. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.20. It's PE Ratio ratio for today is At Loss.

Adverum Biotechnologies's EPS without NRI for the three months ended in Mar. 2024 was $-1.50. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.20. It's PE Ratio without NRI ratio for today is At Loss.


Adverum Biotechnologies Owner Earnings per Share (TTM) Historical Data

The historical data trend for Adverum Biotechnologies's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Owner Earnings per Share (TTM) Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.68 -11.02 -14.90 -14.40 -13.00

Adverum Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.54 -12.99 -12.83 -13.00 -7.97

Competitive Comparison of Adverum Biotechnologies's Owner Earnings per Share (TTM)

For the Biotechnology subindustry, Adverum Biotechnologies's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Price-to-Owner-Earnings falls into.



Adverum Biotechnologies Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Adverum Biotechnologies's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income -112.90
Depreciation, Depletion and Amortization 5.05
Change In Deferred Tax 0.00
5Y Average of Maintenance Capital Expenditure 11.35
Change In Working Capital -12.10
Shares Outstanding (Diluted Average) 16.48

1. Start with "Net Income" from income statement. Adverum Biotechnologies's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-112.90 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Adverum Biotechnologies's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2024 was $5.05 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Adverum Biotechnologies's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $11.35 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Adverum Biotechnologies's 5-Year Average Maintenance Capital Expenditure = $11.35 Mil

5. "Change In Working Capital" is from cashflow statement. Adverum Biotechnologies's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 was $-12.10 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Adverum Biotechnologies's Shares Outstanding (Diluted Average) for the months ended in Mar. 2024 was 16.479 Mil.

Adverum Biotechnologies's Onwer Earnings Per Share for Mar. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( -112.896 +5.049+0
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-11.3484+-12.095)/16.479
=-7.97

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=7.83/-7.97
=0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Adverum Biotechnologies Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (Adverum Biotechnologies) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Executives
C. David Nicholson, director 103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Setareh Seyedkazemi officer: Chief Development Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063
Linda M Rubinstein officer: Chief Financial Officer 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Peter Soparkar officer: Chief Legal Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Brigit Riley officer: Chief Scientific Officer 100 CARDINAL WAY, REDWOOD CITY CA 94063
Laurent Fischer director, officer: CEO and Director C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Richard Beckman officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Nancy E Pecota officer: Principal Accounting Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
John Rakow officer: SVP, Genl Counsel, Acting CFO C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Rupert D'souza officer: Chief Financial Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Soo Hong director C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063
Rabia Gurses Ozden director C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210
James Paul Scopa director 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Julie Clark officer: Chief Medical Officer C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063

Adverum Biotechnologies (Adverum Biotechnologies) Headlines

From GuruFocus

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023

Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 01-18-2023